Modality
Radioligand
MOA
VEGFi
Target
IL-13
Pathway
Cell Cycle
UCCRC
Development Pipeline
Preclinical
Aug 2017
→ Apr 2031
PreclinicalCurrent
NCT05962060
2,694 pts·UC
2024-11→2030-09·Completed
NCT05205092
2,875 pts·CRC
2017-08→2031-04·Recruiting
5,569 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-09-244.5y awayInterim· UC
2031-04-055.0y awayInterim· CRC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Preclinical
Complet…
Catalysts
Interim
2030-09-24 · 4.5y away
UC
Interim
2031-04-05 · 5.0y away
CRC
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05962060 | Preclinical | UC | Completed | 2694 | Biomarker |
| NCT05205092 | Preclinical | CRC | Recruiting | 2875 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Gozeosocimab | Illumina | Phase 2 | BCMA |